Abstract 3020
Background
Oncogenic BRAF-V600 mutations are observed in 1-2% of NSCLC. Targeted therapies (TT) including vemurafenib (V), dabrafenib (D) or dabrafenib plus trametinib (D+T) are associated with favorable outcomes in these patients (pts). The mechanisms of resistance to BRAF-TT in NSCLC are largely unknown.
Methods
We performed genomic profiling of serial ctDNA in 79 metastatic BRAF-mutant NSCLC pts (96% V600E, 4% non-V600). BRAFstatus was ascertained based on local testing. Plasma samples were collected, from 2014-2018 in 27 hospitals, from pts treated with V (n = 34), D (n = 2) or D+T (n = 23). We collected 41 plasma samples at baseline to BRAF-TT, 40 at progressive disease (PD) and ∼200 during treatment follow-up, concurrent to routine radiological evaluation. Inivata InVisionSeq™ assay was used to detect the presence of genomic alterations in 36-cancer related genes.
Results
At baseline, 72.5% of BRAF mutations were detected in plasma. BRAF-V600E detection in plasma was associated with the presence of liver metastasis (22%), versus BRAF-V600E negative pts (7%). Co-occurring alterations at baseline were observed in 18/26 (70%) pts: FGFR2 (1pt), PIK3CA (2pts), ERBB2 (1pt), CTNNB1 (2pts) and IDH1 (2pts). FGFR2, PIK3CAor CTNNB1 alterations were associated with PD as the best response to subsequent BRAF-TT. Complete clearance of baseline BRAF-V600E in ctDNA was observed at the 1stCT-scan evaluation in 42% (3/7) and 82% (9/11) pts who responded to V or D+T, respectively. At PD, a consistent rebound in BRAF-V600E plasma levels was observed in 60% (24/40) pts. PD to V was associated with alterations in the MAPK pathway: KRAS(1pt), GNA11 (1pt), NRASand GNAS (1pt) and MAP2K1and NFE2L2 (1pt). Activating PI3KCA mutations were observed in 4 pts who progressed in < 6 months on V. Similar to pts who progressed on V, alterations in KRAS, NRAS, PIK3CAand CTNNB1were associated with D+T resistance. The impact of these alterations was assessed by in silico structure modeling.
Conclusions
ctDNA monitoring might be an informative tool for assessing disease response and and understand mechanisms of resistance in BRAF-mutant NSCLC pts treated with BRAF-TT. MAPK reactivation remains an important resistance mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sandra Ortiz-Cuaran, David Planchard, Jean-Yves Blay, Pierre Saintigny.
Funding
Fondation ARC (PJA 2017-1206573).
Disclosure
L. Mezquita: Advisory / Consultancy: Roche Diagnostics; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Lectures and educational activities: Tecnofarma; Advisory / Consultancy, Lectures and educational activities: Roche; Advisory / Consultancy, Lectures and educational activities: AstraZeneca; Travel / Accommodation / Expenses: Chugai. J. Mazieres: Advisory / Consultancy: Roche; Research grant / Funding (self): Roche; Advisory / Consultancy: Novartis. K. Howarth: Shareholder / Stockholder / Stock options: Inivata Ltd; Full / Part-time employment: Inivata Ltd. C. Morris: Shareholder / Stockholder / Stock options: Inivata Ltd; Full / Part-time employment: Inivata Ltd. E. Green: Shareholder / Stockholder / Stock options: Inivata Ltd; Full / Part-time employment: Inivata Ltd. M. Perol: Advisory / Consultancy: Roche ; Advisory / Consultancy: Novartis. B. Besse: Research grant / Funding (institution): AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma. J. Blay: Research grant / Funding (institution), Travel grants: Roche; Research grant / Funding (institution), Travel grants: Novartis. P. Saintigny: Advisory / Consultancy: HTG Molecular; Research grant / Funding (institution): BMS, AstraZeneca, Roche, HTG Molecular. D. Planchard: Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, MedImmune, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Research grant / Funding (institution): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho ; Travel / Accommodation / Expenses: AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract